Image: i.dailymail.co.uk
UK drugs giant GlaxoSmithKline and partner XenoPort have received a negative response from the US Food and Drug Administration regarding their marketing application for their restless legs syndrome (RLS) drug.
FULL STORY
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
No comments: